Skip to main content

Table 3 Primary endpoint-related events in the overall population and in patients aged 75 years and older. Reported as N (%) unless otherwise indicated

From: EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Event

Arm A, 100 mg/m2

Arm B, 125 mg/m2

All (N = 79)

Pts aged 75+ (N = 33)

All (N = 79)

Pts aged 75+ (N = 33)

Investigator reported

 Pts with reported event

69 (87)

31 (94)

71 (90)

29 (88)

 PD

61 (77)

28 (85)

60 (76)

23 (70)

 FD

4 (5)

1 (3)

7 (9)

5 (13)

 Death

4 (5)

2 (6)

4 (5)

1 (3)

Central review

 Pts with reported event

72 (91)

32 (97)

74 (94)

30 (91)

 PD

56 (71)

25 (76)

55 (70)

23 (70)

 FD

13 (16)

6 (18)

14 (18)

5 (15)

 Death

3 (4)

1 (3)

5 (6)

2 (6)

  1. FD functional decline, PD disease progression, Pts patients